Medincell Stock Rises Over 2% and Extends Its Rebound to 12% Over a Month
The biotech company from Montpellier continues its recovery in late morning trading, in a Parisian market trending upwards. The stock benefits from new analyst support, adding to an already very favorable annual trajectory.
Portzamparc Raises Its Target to €30 and Reaffirms Its Buy Recommendation
Medincell gains 2.24% to €27.44 during the session, while the SBF 120 index is up 0.29%. This movement occurs as Portzamparc increased its price target from €29.20 to €30.00 on June 3, maintaining its buy recommendation. Based on the current price, this new target offers a potential of about 9.3%. Regarding the pipeline, the European file for olanzapine LAI developed with Teva was accepted by the EMA at the end of May, a step already integrated by the market.
The Stock Remains Above Its Moving Averages Despite a Weekly Decline
At €27.44, the stock is above its 20-day moving average of €27.14 and maintains a comfortable gap with its 50-day moving average at €25.02 (+9.67%). The progress reaches nearly 12% over a month and 71.6% over a year, indicating a solid underlying momentum despite a weekly decline of 3.52%. The RSI at 53 indicates a balance between buyers and sellers, without excess. The resistance of €28.72, already surpassed at the end of May and then lost at the beginning of June, remains the next graphical threshold to monitor to extend the rebound. The technical support reference is at €22.86, more than 16% below the current price.
